摘要
原发性肝癌的潜在病因繁多且起病隐匿,病情的进展受多方面因素影响。免疫治疗与靶向药物治疗一直是作为肝癌常规的非根治性治疗方法,但疗效并不理想,耐药情况不容乐观。近年来16s高通量测序技术的广泛应用与微生物组学的不断深入研究,揭示了微生物在肝癌发生发展中的关键作用。肝脏与口腔、肠道菌群的联系逐渐明确,口腔与肠道的菌群调控为该病开辟了新的治疗方法。综述了口-肠-肝轴的微生物理论基础及其在原发性肝癌治疗上的应用和发展方向。
Primary liver cancer has various potential causes and insidious onset,and its progression is affected by many factors.Immunotherapy and targeted drug therapy have been used as non-radical treatment methods for primary liver cancer,but they cannot achieve a satisfactory effect and may lead to drug resistance.In recent years,the wide application of 16s high-throughput sequencing and the in-depth studies of microbiology have revealed the key role of microorganisms in the development and progression of liver cancer.The association of the liver with oral and intestinal flora is gradually clarified,and the regulation of oral and intestinal flora has brought new treatment methods for the disease.This article reviews the microbial theory of the oral-gut-liver axis and its application and development in the treatment of primary liver cancer.
作者
周铖
张佳铭
郭礼
司海龙
肖海娟
杨林
ZHOU Cheng;ZHANG Jiaming;GUO Li;SI Hailong;XIAO Haijuan;YANG Lin(The First Clinical Medical College,Shaanxi University of Chinese Medicine,Xianyang,Shaanxi 712000,China;The Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310000,China;The Third Department of Oncology,The Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang,Shaanxi 712000,China;State Key Laboratory of Cancer Biology,Xijing Hospital of Digestive Diseases,Air Force Medical University,Xi’an 710032,China;Department of Hepatobiliary Surgery,Xianyang Central Hospital Affiliated to Shaanxi University of Chinese Medicine,Xiangyang,Shaanxi 712000,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2020年第7期1646-1649,共4页
Journal of Clinical Hepatology
基金
中国博士后科学基金面上项目(2017M613351)
陕西中医药大学创新团队(2019-YL06)
陕西省自然科学基金项目(2018JQ8014)。
关键词
肝肿瘤
微生物群
益生元
liver neoplasms
microbiota
prebiotics
作者简介
周铖(1995-),男,主要从事肝癌与消化道菌群相互作用的研究;通信作者:杨林,电子信箱:doctor0523@163.com。
